Development of Angiogenic Cell and Gene Therapy by Transplantation of Umbilical Cord Blood with Vascular Endothelial Growth Factor Gene

Ikeda, Yukihiro; Fukuda, Noboru; Wada, Mika; Matsumoto, Tarô; Satomi, Aya; Yokoyama, Shin-ichiro; Saito, Satoshi; Matsumoto, Koichí; Kanmatsuse, Katsuo; Mugishima, Hideo

doi:10.1291/hypres.27.119

Cited by 55 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The promotion of angiogenesis in ischemic tissue in cardiovascular diseases is at present the subject of intensive research. 3 Angiogenesis can be considered as a series of temporally regulated events involving proteolytic digestion of the extracellular matrix, proliferation and migration of endothelial cells, formation of functional capillaries and remodeling of the vascular bed through apoptosis. A complex network of growth factors and cytokines regulates angiogenesis.…”

Section: Introductionmentioning

confidence: 99%

Zinc-finger transcriptional factor Sall1 induces angiogenesis by activation of the gene for VEGF-A

et al. 2009

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Zinc-finger transcriptional factor Sall1 induces angiogenesis by activation of the gene for VEGF-A

et al. 2009

Self Cite

View full text Add to dashboard Cite

“…PlGF, acting synergistically with vascular endothelial growth factor (VEGF), may be necessary for the maintenance of endothelial cell health during pregnancy (17)(18)(19)(20)(21). The sFlt-1 is an anti-angiogenic protein that antagonizes VEGF and PlGF (21).…”

Section: Introductionmentioning

confidence: 99%

“…The level of PlGF and sFlt-1 changes according to the gestational age; for this reason, we must obtain reference values specific to each gestational age in order to determine whether a given PlGF or sFlt-1 value is normal for a particular gestational age (22,23). However, almost all the previous studies have used only fixed values for PlGF and sFlt-1 instead of employing gestational age-specific reference values (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Recently, we constructed reference values for serum PlGF and SFlt-1 based on a longitudinal analysis of 148 cohorts of pregnant women at various gestational stages (22).…”

Section: Introductionmentioning

confidence: 99%

Alterations in Placental Growth Factor Levels before and after the Onset of Preeclampsia Are More Pronounced in Women with Early Onset Severe Preeclampsia

et al. 2007

View full text Add to dashboard Cite

It has been established that the serum placental growth factor (PlGF) decreases and the soluble fms-like tyrosine kinase-1 (sFlt-1) increases in women with preeclampsia. However, there have been no studies on the relation between preeclampsia onset time and the changes in PlGF and sFlt-1. Furthermore, the PlGF and sFlt-1 levels have not been evaluated using their reference values specific to each gestational age. In this study we reevaluated the serum PlGF and sFlt-1 levels before and after the clinical manifestation of early and late onset severe preeclampsia using the new reference values developed in our recent longitudinal study. Blood specimens were obtained immediately after the clinical manifestation of severe preeclampsia in 34 referred women, and both before and after the clinical manifestation in 8 women receiving a routine checkup at our institute. Both women with early and those with late preeclampsia showed decreased PlGF and increased sFlt-1 levels compared to normotensive controls at 28 and 37 weeks (n =68). However, those with early onset preeclampsia had a higher incidence of low PlGF (<5th percentile on the reference values) and high sFlt-1 ( ≥ 95th percentile) than those with late onset (low PlGF: 93% vs. 55%; high sFlt-1: 100% vs. 60%). log10PlGF (r =0.574, p <0.001) and log10(sFlt-1/PlGF) (r =-0.556, p <0.001) were correlated with the week of onset of preeclampsia. Before the onset of preeclampsia, the incidence rate of low PlGF in the women with early onset preeclampsia was 100% (5/5), whereas that in the women with late onset preeclampsia was 0% (0/2) (p =0.048). Therefore, alterations in the PlGF levels both before and after the onset of preeclampsia may be more pronounced in women with early onset than those with late onset severe

show abstract

“…(Yu et al, 2009) When implanted in vivo, the vegf transfected EPCs stimulated greater blood flow and angiogenesis in animal models of ischemia than EPCs alone. (Ikeda et al, 2004) In spite of the promising results seen with cell therapies, certain limitations still exist. First, the sources of cells for transplantation, either mature cells or progenitor cells, can be problematic.…”

Section: Cell Therapiesmentioning

confidence: 99%

Formation of Stable Vascular Networks in Engineered Tissues

Jiang¹,

Brey²

2011

Regenerative Medicine and Tissue Engineering - Cells and Biomaterials

View full text Add to dashboard Cite

Development of Angiogenic Cell and Gene Therapy by Transplantation of Umbilical Cord Blood with Vascular Endothelial Growth Factor Gene

Abstract: Endothelial progenitor cells (EPCs

Cited by 55 publications

References 24 publications

Zinc-finger transcriptional factor Sall1 induces angiogenesis by activation of the gene for VEGF-A

Zinc-finger transcriptional factor Sall1 induces angiogenesis by activation of the gene for VEGF-A

Alterations in Placental Growth Factor Levels before and after the Onset of Preeclampsia Are More Pronounced in Women with Early Onset Severe Preeclampsia

Formation of Stable Vascular Networks in Engineered Tissues

Contact Info

Product

Resources

About